Literature DB >> 31693255

Comparison of the roles of estrogens and androgens in breast cancer and prostate cancer.

Wen-Jing Liu1, Gang Zhao2, Chen-Yan Zhang1, Chang-Qing Yang1, Xiang-Bin Zeng1, Jin Li1, Kun Zhu1, Shi-Qi Zhao1, Hui-Meng Lu1, Da-Chuan Yin1, Sheng-Xiang Lin3.   

Abstract

Breast cancer (BC) and prostate cancer (PC) are the second most common malignant tumors in women and men in western countries, respectively. The risks of death are 14% for BC and 9% for PC. Abnormal estrogen and androgen levels are related to carcinogenesis of the breast and prostate. Estradiol stimulates cancer development in BC. The effect of estrogen on PC is concentration-dependent, and estrogen can regulate androgen production, further affecting PC. Estrogen can also increase the risk of androgen-induced PC. Androgen has dual effects on BC via different metabolic pathways, and the role of the androgen receptor (AR) in BC also depends on cell subtype and downstream target genes. Androgen and AR can stimulate both primary PC and castration-resistant PC. Understanding the mechanisms of the effects of estrogen and androgen on BC and PC may help us to improve curative BC and PC treatment strategies.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  androgen; breast cancer; estrogen; prostate cancer

Mesh:

Substances:

Year:  2019        PMID: 31693255     DOI: 10.1002/jcb.29515

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  4 in total

1.  Selective Estrogen Receptor Degraders for the Potential Treatment of Cancer.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-03-09       Impact factor: 4.345

2.  PROTAC Compounds Targeting Androgen Receptor for Cancer Therapeutics: Prostate Cancer and Kennedy's Disease.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2020-05-18       Impact factor: 4.345

3.  Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay.

Authors:  Claudia Cipriani; Maria Pires Pacheco; Ali Kishk; Maryem Wachich; Daniel Abankwa; Elisabeth Schaffner-Reckinger; Thomas Sauter
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-31

Review 4.  Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.

Authors:  Dusan Ruzic; Nemanja Djoković; Tatjana Srdić-Rajić; Cesar Echeverria; Katarina Nikolic; Juan F Santibanez
Journal:  Pharmaceutics       Date:  2022-01-16       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.